Small molecule · Antagonist of 5-hydroxytryptamine 3 (5-HT3) receptor (HTR3A) · developed by Roche
Granisetron is a selective 5-HT3 receptor antagonist that blocks serotonin binding at peripheral vagal nerve terminals and central chemoreceptor trigger zone receptors, preventing chemotherapy-induced vomiting signals. A controlled-release formulation encapsulates granisetron in a biodegradable poly(ortho ester) polymer for sustained release. It is studied in chemotherapy-induced nausea and vomiting.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 30, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05434663 | Phase 4 | Chemotherapy-Induced Nausea and Vomiting (CINV) | Active not recruiting | HRTX |
| NCT02106494 | Phase 3 | Chemotherapy-induced Nausea and Vomiting | Completed | HRTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chemotherapy-Induced Nausea and Vomiting (CINV)Nausea and VomitingUnspecified Adult Solid Tumor, Protocol Specific
Updated Nov 15, 2026.